{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T20:33:33Z","timestamp":1778099613023,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"this study was supported by a research grant from the pharmacologic task force of the israeli heart society"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s10557-021-07265-0","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T10:23:20Z","timestamp":1632306200000},"page":"489-496","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Effect of Tafamidis on Circulating Endothelial Progenitor Cells in Patients with Transthyretin Cardiac Amyloidosis"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9259-4808","authenticated-orcid":false,"given":"Osnat","family":"Itzhaki Ben Zadok","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorit","family":"Leshem-Lev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuvia","family":"Ben-Gal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashraf","family":"Hamdan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nili","family":"Schamroth Pravda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tali","family":"Steinmetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irit","family":"Kandinov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilit","family":"Ovadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Kornowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alon","family":"Eisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,22]]},"reference":[{"issue":"6","key":"7265_CR1","doi-asserted-by":"publisher","first-page":"H2305","DOI":"10.1152\/ajpheart.00503.2011","volume":"301","author":"RQ Migrino","year":"2011","unstructured":"Migrino RQ, Truran S, Gutterman DD, Franco DA, Bright M, Schlundt B, et al. Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins. Am J Physiol Heart Circ Physiol. 2011;301(6):H2305\u201312.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"8","key":"7265_CR2","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/eurheartj\/ehm066","volume":"28","author":"KM Modesto","year":"2007","unstructured":"Modesto KM, Dispenzieri A, Gertz M, Cauduro SA, Khandheria BK, Seward JB, et al. Vascular abnormalities in primary amyloidosis. Eur Heart J. 2007;28(8):1019\u201324.","journal-title":"Eur Heart J"},{"issue":"1","key":"7265_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/biomedicines7010011","volume":"7","author":"H Koike","year":"2019","unstructured":"Koike H, Katsuno M. Ultrastructure in transthyretin amyloidosis: from pathophysiology to therapeutic insights. Biomedicines. 2019;7(1):11.","journal-title":"Biomedicines"},{"issue":"3","key":"7265_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0002-9343(00)00471-X","volume":"109","author":"PS Mueller","year":"2000","unstructured":"Mueller PS, Edwards WD, Gertz MA. Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med. 2000;109(3):181\u20138.","journal-title":"Am J Med"},{"issue":"4","key":"7265_CR5","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jchf.2014.03.009","volume":"2","author":"S Dorbala","year":"2014","unstructured":"Dorbala S, Vangala D, Bruyere J Jr, Quarta C, Kruger J, Padera R, et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail. 2014;2(4):358\u201367.","journal-title":"JACC Heart Fail"},{"issue":"11","key":"7265_CR6","doi-asserted-by":"publisher","first-page":"838","DOI":"10.7326\/0003-4819-131-11-199912070-00007","volume":"131","author":"J Al Suwaidi","year":"1999","unstructured":"Al Suwaidi J, Velianou JL, Gertz MA, Cannon RO 3rd, Higano ST, Holmes DR Jr, et al. Systemic amyloidosis presenting with angina pectoris. Ann Intern Med. 1999;131(11):838\u201341.","journal-title":"Ann Intern Med"},{"issue":"10","key":"7265_CR7","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1056\/NEJMoa043814","volume":"353","author":"N Werner","year":"2005","unstructured":"Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353(10):999\u20131007.","journal-title":"N Engl J Med"},{"issue":"1","key":"7265_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00395-003-0441-3","volume":"99","author":"S Rupp","year":"2004","unstructured":"Rupp S, Badorff C, Koyanagi M, Urbich C, Fichtlscherer S, Aicher A, et al. Statin therapy in patients with coronary artery disease improves the impaired endothelial progenitor cell differentiation into cardiomyogenic cells. Basic Res Cardiol. 2004;99(1):61\u20138.","journal-title":"Basic Res Cardiol"},{"issue":"11","key":"7265_CR9","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316.","journal-title":"N Engl J Med"},{"key":"7265_CR10","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.amjcard.2020.07.050","volume":"133","author":"OIB Zadok","year":"2020","unstructured":"Itzhaki Ben Zadok O, Eisen A, Shapira Y, Monakier D, Iakobishvili Z, Schwartzenberg S, et al. Natural history and disease progression of early cardiac amyloidosis evaluated by echocardiography. Am J Cardiol. 2020;133:126\u201333.","journal-title":"Am J Cardiol"},{"issue":"4","key":"7265_CR11","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCRESAHA.111.243386","volume":"110","author":"GP Fadini","year":"2012","unstructured":"Fadini GP, Losordo D, Dimmeler S. Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res. 2012;110(4):624\u201337.","journal-title":"Circ Res"},{"issue":"3","key":"7265_CR12","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1161\/01.RES.0000205765.28940.93","volume":"98","author":"EB Friedrich","year":"2006","unstructured":"Friedrich EB, Walenta K, Scharlau J, Nickenig G, Werner N. CD34-\/CD133+\/VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities. Circ Res. 2006;98(3):e20\u20135.","journal-title":"Circ Res"},{"issue":"8","key":"7265_CR13","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.tcm.2004.10.001","volume":"14","author":"C Urbich","year":"2004","unstructured":"Urbich C, Dimmeler S. Endothelial progenitor cells functional characterization. Trends Cardiovasc Med. 2004;14(8):318\u201322.","journal-title":"Trends Cardiovasc Med"},{"issue":"4","key":"7265_CR14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1620\/tjem.227.321","volume":"227","author":"EK Kim","year":"2012","unstructured":"Kim EK, Lee JH, Jeong HC, Oh D, Hwang SG, Cho YW, et al. Impaired colony-forming capacity of circulating endothelial progenitor cells in patients with emphysema. Tohoku J Exp Med. 2012;227(4):321\u201331.","journal-title":"Tohoku J Exp Med"},{"key":"7265_CR15","doi-asserted-by":"publisher","first-page":"37450","DOI":"10.1038\/srep37450","volume":"6","author":"CP Chou","year":"2016","unstructured":"Chou CP, Jiang SS, Pan HB, Yen YC, Tseng HH, Hung YT, et al. Endothelial cell colony forming units derived from malignant breast diseases are resistant to tumor necrosis factor-\u03b1-induced apoptosis. Sci Rep. 2016;6:37450.","journal-title":"Sci Rep"},{"issue":"7","key":"7265_CR16","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1056\/NEJMoa022287","volume":"348","author":"JM Hill","year":"2003","unstructured":"Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348(7):593\u2013600.","journal-title":"N Engl J Med"},{"issue":"2","key":"7265_CR17","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1161\/01.ATV.0000114236.77009.06","volume":"24","author":"J Hur","year":"2004","unstructured":"Hur J, Yoon CH, Kim HS, Choi JH, Kang HJ, Hwang KK, et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol. 2004;24(2):288\u201393.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"7265_CR18","first-page":"835934","volume":"2015","author":"CR Balistreri","year":"2015","unstructured":"Balistreri CR, Buffa S, Pisano C, Lio D, Ruvolo G, Mazzesi G. Are endothelial progenitor cells the real solution for cardiovascular diseases? Focus on controversies and perspectives. Biomed Resh Int. 2015;2015:835934.","journal-title":"Biomed Resh Int"},{"issue":"21","key":"7265_CR19","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1093\/eurheartj\/ehq184","volume":"31","author":"EI Lev","year":"2010","unstructured":"Lev EI, Leshem-Lev D, Mager A, Vaknin-Assa H, Harel N, Zimra Y, et al. Circulating endothelial progenitor cell levels and function in patients who experienced late coronary stent thrombosis. Eur Heart J. 2010;31(21):2625\u201332.","journal-title":"Eur Heart J"},{"issue":"2","key":"7265_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.yjmcc.2003.10.005","volume":"36","author":"JZ Chen","year":"2004","unstructured":"Chen JZ, Zhu JH, Wang XX, Zhu JH, Xie XD, Sun J, et al. Effects of homocysteine on number and activity of endothelial progenitor cells from peripheral blood. J Mol Cell Cardiol. 2004;36(2):233\u20139.","journal-title":"J Mol Cell Cardiol"},{"issue":"24","key":"7265_CR21","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404\u201312.","journal-title":"Circulation"},{"issue":"35","key":"7265_CR22","doi-asserted-by":"publisher","first-page":"4535","DOI":"10.2174\/0929867324666171012110244","volume":"25","author":"A Ruggeri","year":"2018","unstructured":"Ruggeri A, Paviglianiti A, Volt F, Kenzey C, Rafii H, Rocha V, et al. Endothelial and circulating progenitor cells in hematological diseases and allogeneic hematopoietic stem cell transplantation. Curr Med Chem. 2018;25(35):4535\u201344.","journal-title":"Curr Med Chem"},{"issue":"1","key":"7265_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.carrev.2010.01.001","volume":"12","author":"GP Lasala","year":"2011","unstructured":"Lasala GP, Silva JA, Kusnick BA, Minguell JJ. Combination stem cell therapy for the treatment of medically refractory coronary ischemia: a phase I study. Cardiovasc Revasc Med. 2011;12(1):29\u201334.","journal-title":"Cardiovasc Revasc Med"},{"issue":"44","key":"7265_CR24","doi-asserted-by":"publisher","first-page":"31752","DOI":"10.1074\/jbc.M113.469858","volume":"288","author":"RJ Nunes","year":"2013","unstructured":"Nunes RJ, de Oliveira P, Lages A, Becker JD, Marcelino P, Barroso E, et al. Transthyretin proteins regulate angiogenesis by conferring different molecular identities to endothelial cells. J Biol Chem. 2013;288(44):31752\u201360.","journal-title":"J Biol Chem"},{"issue":"3","key":"7265_CR25","doi-asserted-by":"publisher","first-page":"991","DOI":"10.4049\/jimmunol.1800736","volume":"202","author":"CC Lee","year":"2019","unstructured":"Lee CC, Ding X, Zhao T, Wu L, Perkins S, Du H, et al. Transthyretin stimulates tumor growth through regulation of tumor, immune, and endothelial cells. J Immunol. 2019;202(3):991\u20131002.","journal-title":"J Immunol"},{"issue":"21","key":"7265_CR26","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1212\/WNL.0000000000003362","volume":"87","author":"H Koike","year":"2016","unstructured":"Koike H, Ikeda S, Takahashi M, Kawagashira Y, Iijima M, Misumi Y, et al. Schwann cell and endothelial cell damage in transthyretin familial amyloid polyneuropathy. Neurology. 2016;87(21):2220\u20139.","journal-title":"Neurology"},{"issue":"2","key":"7265_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40120-020-00210-7","volume":"9","author":"H Koike","year":"2020","unstructured":"Koike H, Katsuno M. Transthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapies. Neurol Ther. 2020;9(2):317\u201333.","journal-title":"Neurol Ther"},{"issue":"6","key":"7265_CR28","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ejhf.2198","volume":"23","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Bengel F, Brito D, Damy T, Duca F, Dorbala S, et al. Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2021;23(6):895\u2013905.","journal-title":"Eur J Heart Fail"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07265-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-021-07265-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07265-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T07:17:44Z","timestamp":1652167064000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-021-07265-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,22]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["7265"],"URL":"https:\/\/doi.org\/10.1007\/s10557-021-07265-0","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,22]]},"assertion":[{"value":"11 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Rabin Medical Center Review Board<b>.<\/b> All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"OIBZ has served on advisory boards for Pfizer and has received speaking fees from Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"All patients given their written informed consent to participate in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}